{"entity":{"id":"paper-nguyen-trastuzumab-adjuvant-cea-vietnam-plos-one-2024","kind":"paper","name":"Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam","aka":[],"tldr":"Trastuzumab is reimbursed at 60% by Viet Nam's social health insurance; this model found a year of adjuvant trastuzumab cost 519.6 million dong (22,845 US dollars) per quality-adjusted life year gained, above thresholds of one and three times GDP per head.","summary":"A Markov model from a societal perspective compared one year of adjuvant trastuzumab with chemotherapy against chemotherapy (paclitaxel) alone in early HER2-positive breast cancer, using efficacy from the N9831, NSABP B-31, HERA and BCIRG 006 trials and Vietnamese costs and utilities. The authors state that trastuzumab is included in the social health insurance benefits package with a reimbursement rate of 60%.\n\nTrastuzumab added 888,453,971 dong (39,062 US dollars), 3.09 life years and 1.61 quality-adjusted life years, an incremental cost-effectiveness ratio of 519,616,972 dong (22,845 US dollars) per quality-adjusted life year.","asOf":"2026-11-04","links":[{"label":"PLoS One 2024","url":"https://doi.org/10.1371/journal.pone.0300474"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38489305/"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab","trastuzumab-biosimilars"],"companies":[],"institutions":["vss-vietnam"],"pathways":[],"terms":["hta"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"PLoS One","year":2024,"doi":"10.1371/journal.pone.0300474","pmid":"38489305","authors":"Nguyen AQ, Tran OTM, Nguyen PK, Nguyen HT","paperType":"methods","findings":["Incremental cost per quality-adjusted life year gained: 519,616,972 dong (22,845 US dollars); per life year gained: 287,390,682 dong (12,635 US dollars).","The ratio exceeds thresholds of one and three times GDP per head by 6.3 and 2.1 times.","It would be cost-effective at three times GDP per head if the prices of the 150 mg and 450 mg vials fell by 56% and 54%."],"whatItMeans":"Trastuzumab works in HER2-positive breast cancer; the question this paper answers for Viet Nam is price. It gives the payer the price reductions, or biosimilars and vial sharing, that would bring the medicine within common thresholds.","caveats":["A model built on trial efficacy, not observed Vietnamese outcomes.","Results were driven mainly by transition probabilities and the trastuzumab price."]},"route":"/key-papers/paper-nguyen-trastuzumab-adjuvant-cea-vietnam-plos-one-2024/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/"}],"institution":[{"id":"moh-vietnam","kind":"institution","name":"Ministry of Health, Viet Nam","route":"/institutions/moh-vietnam/"},{"id":"vss-vietnam","kind":"institution","name":"Vietnam Social Security","route":"/institutions/vss-vietnam/"}],"term":[{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"}]}}